The Role of the Incretin Hormones GIP and GLP-1 in the Pathogenesis of Type 2 Diabetes

被引：0
|
作者：
Meier, J. J. [1 ]
机构：
[1] Klinikum Ruhr Univ Bochum, St Josef Hosp, Med Klin 1, D-44791 Bochum, Germany
来源：
DIABETOLOGIE UND STOFFWECHSEL | 2009年 / 4卷 / 05期
关键词：
GASTRIC-INHIBITORY POLYPEPTIDE; GLUCAGON-LIKE PEPTIDE-1; DEPENDENT INSULINOTROPIC POLYPEPTIDE; 1ST-DEGREE RELATIVES; ORAL GLUCOSE; RECEPTOR EXPRESSION; 7-36; AMIDE; SECRETION; PLASMA; HYPERGLYCEMIA;
D O I：
10.1055/s-0029-1224610
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
The incretin effect, i.e. the postprandial augmentation of insulin secretion by gastrointestinal hormones, mediates similar to 50-70% of the meal-related increments in insulin secretion in healthy individuals. In contrast, the incretin effect is almost completely absent in patients with type 2 diabetes. The impaired incretin effect in type 2 diabetes has been mainly attributed to the reduced insulinotropic activity of GIP, whereas the actions of GLP-1 are largely preserved. Furthermore, a diminished secretion of GLP-1 has been suggested to contribute to the impaired incretin effect in type 2 diabetes, but this finding has not been confirmed in the majority of studies. This article aims to compare the secretion and action of the incretins GIP and GLP-1 between patients with type 2 diabetes and healthy individuals. In addition, the importance of alterations in the entero-insular axis for the pathogenesis of type 2 diabetes will be discussed.
引用
收藏
页码：295 / 300
页数：6
相关论文
共 50 条
  • [41] Human duodenal enteroendocrine cells: source of both incretin peptides, GLP-1 and GIP
    Theodorakis, MJ
    Carlson, O
    Michopoulos, S
    Doyle, ME
    Juhaszova, M
    Petraki, K
    Egan, JM
    AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM, 2006, 290 (03): : E550 - E559
  • [42] The role of GLP-1 in the enteroinsulinar axis in type 2 diabetes mellitus
    Bedorf, A.
    Kutscherauer, G.
    Nicolaus, M.
    Goeke, B.
    Schirra, J.
    DIABETOLOGIA, 2009, 52 : S106 - S106
  • [43] The role of GLP-1 in the postprandial effects of acarbose in type 2 diabetes
    Dalsgaard, Niels B.
    Gasbjerg, Laerke S.
    Hansen, Laura S.
    Hansen, Nina L.
    Stensen, Signe
    Hartmann, Bolette
    Rehfeld, Jens F.
    Holst, Jens J.
    Vilsboll, Tina
    Knop, Filip K.
    EUROPEAN JOURNAL OF ENDOCRINOLOGY, 2021, 184 (03) : 383 - 394
  • [44] Research Progress on the GIP/GLP-1 Receptor Coagonist Tirzepatide, a Rising Star in Type 2 Diabetes
    Ma, Zijun
    Jin, Kaiqin
    Yue, Mengmeng
    Chen, Xin
    Chen, Jun
    JOURNAL OF DIABETES RESEARCH, 2023, 2023
  • [45] Dual GIP/GLP-1 receptor agonists: New advances for treating type-2 diabetes
    Scheen, Andre J.
    ANNALES D ENDOCRINOLOGIE, 2023, 84 (02) : 316 - 321
  • [46] Different Effects of Meal and Incretin Hormones GIP and GLP-1 on Splanchnic Organs' Blood Flow in Healthy and Morbidly Obese Subjects
    Koffert, Jukka
    Honka, Henri
    Kauhanen, Saila
    Kudomi, Nobuyuki
    Lindqvist, Andreas
    Wierup, Nils
    Groop, Leif
    Nuutila, Pirjo
    DIABETES, 2015, 64 : A529 - A529
  • [47] GIP and GLP-1: Stepsiblings Rather Than Monozygotic Twins Within the Incretin Family
    Nauck, Michael A.
    Meier, Juris J.
    DIABETES, 2019, 68 (05) : 897 - 900
  • [48] Physiology of the Incretin Hormones, GIP and GLP-1-Regulation of Release and Posttranslational Modifications
    Holst, Jens J.
    Albrechtsen, Nicolai J. Wewer
    Rosenkilde, Mette M.
    Deacon, Carolyn F.
    COMPREHENSIVE PHYSIOLOGY, 2019, 9 (04) : 1339 - 1381
  • [49] Different mechanisms of GIP and GLP-1 action explain their different therapeutic efficacy in type 2 diabetes
    Grespan, Eleonora
    Giorgino, Toni
    Natali, Andrea
    Ferrannini, Ele
    Mari, Andrea
    METABOLISM-CLINICAL AND EXPERIMENTAL, 2021, 114
  • [50] Incretin hormones and type 2 diabetes
    Michael A. Nauck
    Timo D. Müller
    Diabetologia, 2023, 66 : 1780 - 1795
12345